z-logo
open-access-imgOpen Access
Effect of erythrinaline alkaloids from Erythrina lysistemon on human recombinant caspase-3
Author(s) -
Armwood Shanta,
Faviola Bernard,
Japheth O. Ombito,
R. T. Majinda Runner,
T. Gwebu Ephraim
Publication year - 2018
Publication title -
african journal of pharmacy and pharmacology
Language(s) - English
Resource type - Journals
ISSN - 1996-0816
DOI - 10.5897/ajpp2016.4628
Subject(s) - recombinant dna , apoptosis , caspase , chemistry , caspase 3 , effector , programmed cell death , cancer cell , cancer , pharmacology , biochemistry , biology , gene , genetics
Prostate cancer is a leading killer disease among men all over the world. Inducing apoptosis (programmed cell death) is a strategic chemotherapeutic approach. Caspase-3 is a key effector of apoptosis, and its activation promotes apoptosis. It was hypothesized that erythrinaline alkaloids activate caspase-3. The alkaloids were isolated from the flowers and pods of Erythrina lysistemon. Their effect on human recombinant caspase-3 was studied. This study reports that three erythrinaline alkaloids (+)-11α-hydroxyerysotrine N-oxide (1), (+)-11β-hydroxyerysotrine N-oxide (2) and (+)-11β-methoxyerysotrine N-oxide (3) activated human recombinant caspase-3 in a dose-dependent manner. Compound 1 and 2 increased the activity by five-fold while compound 3 increased it by ten-fold. Erythrinaline alkaloids exhibit remarkable ability to activate caspase-3 and may be lead compounds as potential therapeutics for the treatment of cancer as inducers of apoptosis in cancer cells. Key words: Erythrinaline alkaloids, human recombinant caspase-3, apoptosis, prostate cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom